Prevalence and predictors of highly active antiretroviral therapy use in patients with HIV infection in the United States

Journal of Acquired Immune Deficiency Syndromes

Volumn 25, Issue 2, 2000, Pages 115-123

  Cunningham, William E ^a,g   Markson, Leona E ^b   Andersen, Ronald M ^a   Crystal, Stephen H ^c   Fleishman, John A ^d   Golin, Carol ^e   Gifford, Allen ^h   Liu, Honghu H ^a   Nakazono, Terry T ^a   Morton, Sally ^f   Bozzette, Samuel A ^f   Shapiro, Martin F ^a,f   Wenger, Neil S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c RUTGERS UNIVERSITY   (United States)

^d AGENCY FOR HEALTHCARE RESEARCH AND QUALITY   (United States)

^e UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^f RAND CORPORATION   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h NONE

Author keywords

AIDS; HAART use; HIV

Indexed keywords

ANTIRETROVIRUS AGENT;

ADULT; ARTICLE; CLINICAL PROTOCOL; COHORT ANALYSIS; CONTROLLED STUDY; DRUG UTILIZATION; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PRACTICE GUIDELINE; PREDICTION; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RACE DIFFERENCE; SOCIOECONOMICS; UNITED STATES;

EID: 0034298814     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200010010-00005     Document Type: Article

References (27)

1. Antiretroviral therapy for HIV infection in 1996
2. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
3. Improved survival among HIV-infected individuals following initiation of antiretrovirals
4. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration
5. Self-reported antiretroviral therapy in injection drug users
6. Variations in the care of HIV-infected adults in the United States. Results from the HIV Cost and Services Utilization Study
7. Access of vulnerable groups to antiretroviral therapy among persons in care for HIV disease in the U.S.
8. The diffusion of innovation in AIDS treatment: Zidovudine use in two New Jersey cohorts
9. National probability samples in studies of low-prevalence diseases, part 1: Perspectives and lessons learned from the HIV Cost and Services Utilization Study
10. The care of HIV-infected adults in the United States: Results from the HIV Cost and Services Utilization Study
11. National probability samples in studies of low-prevalence diseases, part 2: Designing and implementing the HIV Cost and Services Utilization study sample
12. Use of space-filling curves in generating a national rural sampling frame for HIV/AIDS research
13. Inference from complex samples
14. Handling missing data in survey research
15. Henry J. Kaiser Family Foundation Panel on clinical practices for treatment of HIV infection: Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents
16. Prevalence and predictors of unmet need for supportive services among HIV-infected persons: Impact of case management
17. Racial and ethnic differences in outcome in zidovudine-treated patients with advanced HIV disease
18. Racial differences in the use of drug therapy for HIV disease in an urban community
19. Compliance with public sector HIV medical care
20. Access and use of medications in HIV disease
21. Barriers to use of free antiretroviral therapy in injection drug users
22. Adherence to guidelines for antiretroviral therapy and for preventing opportunistic infections in HIV-infected adults and adolescents in Ryan Whitefunded facilities in the United States
23. Why is highly active antiretroviral therapy (HAART) not prescribed or discontinued, a Swiss cohort study
24. Differential decline in AIDS mortality by gender and race/ethnicity in New York City
25. Declines in AIDS-related mortality and factors associated with recent AIDS deaths in Seattle-King County, Washington